The Global Animal Therapeutics And Diagnostics Market Is Attributed To The Initiatives Taken By The Government To Spend More On Healthcare And R&D. In Addition, The Increase In The Consumption Of Meat, Milk, Protein, And The Extensively Growing Pet Ownership Drive The Market. However, Lack Of Awareness Regarding Pet Health And Ill Effects Of Excessive Drug Dosage Are Expected To Restrain The Growth Of The Market.
The Global Animal Therapeutics And Diagnostics Market Report Provides An Extensive Analysis Of The Current Market Trends And Future Estimations Prevailing In The Market.
The Market Estimations From 2014 To 2022 Are Based On High-End Analysis Of The Key Developments.
The Market Scenario Is Comprehensively Analyzed With Respect To The Product Type, Animal Type, And Geography.
Recent Developments And Key Manufacturers Are Listed And Analyzed To Understand The Competitive Market Scenario.
In-Depth Analysis, Based On Geography Provides An Understanding Of The Regional Market, Which Assists In Strategic Business Planning.
Animal Therapeutics and Diagnostics Market Key Segments
Animal Diagnostics Products
Animal Therapeutics Products
Anti-Parasitic Drugs And Antibiotics
By Animal Type
Other Companion Animals
Rest Of Europe
Rest Of Asia-Pacific
Rest Of Lamea
The Key Players Profiled In This Report Include
Eli Lilly And Company
Merck & Co., Inc.
Ceva Santé Animale
The Other Players Of The Animal Therapeutics And Diagnostics Market Include (Companies Not Profiled In The Report):
Active Motif, Inc.
Takara Bio Usa, Inc.
Candor Bioscience Gmbh
Innova Biosciences Ltd.
Agilent Technologies, Inc.
Nanotemper Technologies Gmbh
1.1. REPORT DESCRIPTION
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3 MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Government regulations
3.3.1. Center for Veterinary Medicine (CVM)
3.3.2. Environmental Protection Agency (EPA)
3.4. Patents Analysis
3.4.1. PATENT ANALYSIS BY YEAR
22.214.171.124. Patent analysis of animal therapeutics by year
126.96.36.199. Patent analysis of animal diagnostics by year
3.4.2. PATENT ANALYSIS BY REGION
188.8.131.52. Patent analysis of animal diagnostics by region
184.108.40.206. Patent analysis of animal diagnostics by region
3.5. Market dynamics
220.127.116.11. Rising demand for animal derived food products
18.104.22.168. Growing demand for pet insurance
22.214.171.124. Rising concern to prevent zoonotic diseases
126.96.36.199. Growing ownership of companion animals
188.8.131.52. Rising animal health expenditure
184.108.40.206. Highly competitive meat and milk prices
220.127.116.11. Lack of animal health awareness
18.104.22.168. Adverse impact of veterinary drugs on human and animal health
22.214.171.124. Advancement in therapeutic and diagnostic products
126.96.36.199. Therapeutic and diagnostic products for hybrid animals
CHAPTER 4 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1.1. Market size and forecast
4.2. animal diagnostics products
4.2.1. Market size and forecast
188.8.131.52. Key market trends
184.108.40.206. Key growth factors and opportunities
220.127.116.11. Key market trends
18.104.22.168. Key growth factors and opportunities
4.3. animal therapeutics products
4.3.1. Market size and forecast
4.3.2. Anti-Parasitic drugs and antibiotics
22.214.171.124. Key market trends
126.96.36.199. Key growth factors and opportunities
4.3.3. Anti-Inflammatory drugs
188.8.131.52. Key market trends
184.108.40.206. Key growth factors and opportunities
220.127.116.11. Key market trends
18.104.22.168. Key growth factors and opportunities
22.214.171.124. Key market trends
126.96.36.199. Key growth factors and opportunities
CHAPTER 5 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY ANIMAL TYPE
5.1.1. Market size and forecast
5.2. Companion Animals
5.2.1. Market size and forecast
5.2.4. Other Companion Animals
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5.1. Market size and forecast
5.6.1. Market size and forecast
CHAPTER 6 ANIMAL THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size & forecast
6.2.5. Canada market size and forecast
6.2.6. Mexico market size and forecast
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany market size and forecast
6.3.5. France market size and forecast
6.3.6. UK market size and forecast
6.3.7. Italy market size and forecast
6.3.8. Rest of Europe market size and forecast
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan market size and forecast
6.4.5. China market size and forecast
6.4.6. Australia market size and forecast
6.4.7. India market size and forecast
6.4.8. South Korea market size and forecast
6.4.9. Taiwan market size and forecast
6.4.10. Rest of Asia-Pacific market size and forecast
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size and forecast
6.5.5. Turkey market size and forecast
6.5.6. Venezuela market size and forecast
6.5.7. Saudi Arabia market size and forecast
6.5.8. Rest of LAMEA market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. Bayer AG
7.1.1. Company overview
7.1.2. Operating business segments
7.1.3. Business performance
7.1.4. Key strategic moves & developments
7.2. Eli Lilly and Company
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Business performance
7.2.4. Key strategic moves & developments
7.3. Boehringer, Ingelheim GmbH
7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Business performance
7.4. Merck & Co.
7.4.1. Company overview
7.4.2. Business performance
7.4.3. Key strategic moves & developments
7.5. Zoetis Inc.
7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Business performance
7.6. Ceva Sant Animale
7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Business performance
7.7. Sanofi S.A.
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Business performance
7.7.4. Key strategic moves & developments
7.8. Nutreco N.V.
7.8.1. Company overview
7.8.2. Operating business segments
7.8.3. Business performance
7.9. Virbac S.A.
7.9.1. Company overview
7.9.2. Business performance
7.9.3. Key strategic moves & development
*Details on financial performance, strategic moves and developments may not be captured for unlisted companies.
*Please note this is a tentative TOC and may change with research proceedings.
Animal diagnostics is essential to ensure better understanding of the cause of any ailment. Animal diagnostics consists of various instruments and consumables, which can assist in the diagnosis of diseases, whereas therapeutic agents are useful in the treatment of diseases via their mode of action. Animal diagnostics involves determition of the factors responsible for the onset of any disease and transmission of the same. This determition is done by diagnostic instruments and consumables. Therapeutic products used in the treatment of animals comprise of different drugs that help cure the disease through their mode of action.
Increase in number of animal population in the developing countries, rise in demand for animal-based foods, and the rise in adoption of companion animals is the major factor that fuels the growth of this market. The animal therapeutics and diagnostics market has experienced moderate growth in the recent years due to emerging diseases affecting livestock. The outbreak of epidemics results in severe mass wipeouts of animals and is a growing concern for the industries dependent on products obtained through farm animals. Moreover, zoonotic diseases affecting animals pose a threat to the public health making diagnosis and therapeutic products an important component in disease magement.
Animal therapeutics segment is anticipated to domite the market with maximum share, in 2015 in terms of revenue. Therapeutic products are used for the treatment of various animal diseases. The treatment of diseases that affect commercial animals such as poultry and cattle is even more important, as their products in the form of milk and meat can be consumed by humans, which can lead to foodborne diseases in case of infected animals.
Companion animals is expected to be the fastest growing segment throughout the alysis period and accounts for almost one-thirds of the total share of the market in 2015. This is due to the increase in adoption rate of these animals, presence of strong bond between the owner and their companion animals, and high disposable income of the owners.
Key findings of the Animal Diagnostics and Therapeutics Market
Consumables is projected to be the fastest growing segment during the alysis period.
Anti-parasitic drugs generated the highest revenue and is expected to continue its domince throughout the forecast period.
North America domited the global animal therapeutics and diagnostics market and is projected to grow at a CAGR of 5.4%.
Consumable animals segment occupied nearly one-third of the total market in 2015.
Chi is the fastest growing country in the Asia-Pacific region, registering a CAGR of 7.8% from 2016 to 2022.
In 2015, North America displayed maximum contribution in the animal diagnostics segment accounting for one-third of the total revenue generated that year. North America also was the highest contributor in the growth of the market for therapeutics in 2015. Asia-Pacific region observes fast paced growth in both animal diagnostics and animal therapeutics market registering a CAGR of 7.8% and 6.6%, respectively. Rise in disposable income, increase in animal healthcare expenditure, and increase in trend of adopting companion animals boost the growth of the animal therapeutics and diagnostics market in the Asia-Pacific region.
The major companies profiled in the report provide extensive competitive alysis and profiles of key market players including Bayer AG, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Nutreco N.V., and Virbac S.A.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.